Obesity and hormone therapy in breast cancer: An unfinished puzzle

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages 3405-3407

  Goodwin, Pamela J ^a   Pritchard, Kathleen I ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; LETROZOLE; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

BODY MASS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG EFFICACY; EDITORIAL; HUMAN; METASTASIS; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BREAST TUMOR; FEMALE; MENOPAUSE; NOTE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MENOPAUSE; NITRILES; OBESITY; TAMOXIFEN; TRIAZOLES;

EID: 77955295603     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.5113     Document Type: Editorial

References (13)

1. Cleary MP, Grossmann ME: Minireview: Obesity and breast cancer - The estrogen connection. Endocrinology 150:2537-2542, 2009
2. Renehan AG, Roberts DL, Dive C: Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem 114:71-83, 2008 (Pubitemid 351998746)
3. Sestak I, Distler W, Forbes JF, et al: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415, 2010
4. Schmid P, Possinger K, Bohm R, et al: Body mass index as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate. Proc Am Soc Clin Oncol 19:103a, 2000 (abstr 398)
5. Buzdar AU, Rubin S, Steinberg M, et al: The efficacy of anastrozole is not dependent upon body mass index (BMI) in postmenopausal women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 21:55a, 2002 (abstr 219)
6. Jonat W, Howell A, Blomqvist C, et al:. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996
7. Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group. Cancer 79:730-739, 1997 (Pubitemid 27076339)
8. Ward HW: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J 1:13-14, 1973
9. Takatsuka Y, Yayoi E, Inaji H, et al: A comparison of two doses of tamoxifen in patients with advanced breast cancer: 20 mg/day versus 40 mg/day [in Japanese]. Gan To Kagaku Ryoho 16:2093-2097, 1989 (Pubitemid 19168808)
10. Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
11. Lonning PE: Pharmacology of new aromatase inhibitors. The Breast 5:202-208, 1996
12. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: Time for action. J Clin Oncol 27:3271-3273, 2009
13. Ballard-Barbash R, Hunsberger S, Alciati MH, et al: Physical activity, weight control, and breast cancer risk and survival: Clinical trial rationale and design considerations. J Natl Cancer Inst 101:630-643, 2009